Search

Your search keyword '"Glioblastoma drug therapy"' showing total 677 results

Search Constraints

Start Over You searched for: Descriptor "Glioblastoma drug therapy" Remove constraint Descriptor: "Glioblastoma drug therapy" Topic antineoplastic agents, alkylating Remove constraint Topic: antineoplastic agents, alkylating
677 results on '"Glioblastoma drug therapy"'

Search Results

1. AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage.

2. Temozolomide use in elderly patients with MGMT promoter unmethylated glioblastoma: Is it finally time to dismount a dead horse?

3. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients.

4. Use of surface-modified porous silicon nanoparticles to deliver temozolomide with enhanced pharmacokinetic and therapeutic efficacy for intracranial glioblastoma in mice.

5. Implementing a Standardized Educational Tool for Patients With Brain Tumors Undergoing Concurrent Temozolomide and Radiation Therapy.

6. Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma.

7. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance.

8. Neuropilin-1 enhances temozolomide resistance in glioblastoma via the STAT1/p53/p21 axis.

9. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O 6 -methylguanine DNA methyltransferase (MGMT).

10. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme-A Literature Review and Clinical Outcomes.

11. Letter: Efficacy and Safety of Carmustine Wafer Implantation After Ventricular Opening in Glioblastomas, Isocitrate Dehydrogenase-Wildtype, in Adults.

12. In Reply: Efficacy and Safety of Carmustine Wafer Implantation After Ventricular Opening in Glioblastomas, Isocitrate Dehydrogenase-Wildtype, in Adults.

13. Loss of PTPRS elicits potent metastatic capability and resistance to temozolomide in glioblastoma.

14. Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study.

15. Association of temozolomide with progressive multifocal leukoencephalopathy: a disproportionality analysis integrated with network pharmacology.

16. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.

17. Survival Impact of Combined Biguanide and Temozolomide in Glioblastoma Preclinical Models: A Systematic Review and Meta-Analysis.

18. Crocetin Enhances Temozolomide Efficacy in Glioblastoma Therapy Through Multiple Pathway Suppression.

19. ProNGF Expression and Targeting in Glioblastoma Multiforme.

20. Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.

21. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.

22. Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma.

23. Mechanism-based design of agents that selectively target drug-resistant glioma.

24. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.

25. The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro.

26. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.

27. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.

28. Differential effects of radiation fractionation regimens on glioblastoma.

29. Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.

30. [MGMT and temozolomide sensibility].

31. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.

32. Pharmacological Strategy for Selective Targeting of Glioblastoma by Redox-active Combination Drug - Comparison With the Chemotherapeutic Standard-of-care Temozolomide.

33. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.

34. Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.

35. Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.

36. Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models.

37. Antioxidant responses related to temozolomide resistance in glioblastoma.

38. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.

39. Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment.

40. Autophagy inhibition reinforces stemness together with exit from dormancy of polydisperse glioblastoma stem cells.

41. Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma.

42. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.

43. Temozolomide-induced aplastic anaemia: Case report and review of the literature.

44. Central diabetes insipidus induced by temozolomide: A report of two cases.

45. Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma.

46. MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.

47. Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.

48. Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma.

49. Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.

50. Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma.

Catalog

Books, media, physical & digital resources